Cargando…

Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?

OBJECTIVES: The aim of this study was to evaluate the changes in lesion volume on serial multiparametric magnetic resonance (mpMRI) during active surveillance for prostate cancer. METHODS: A total of 160 patients with a targeted biopsy-confirmed visible lesion on mpMRI, stratified by low- and interm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giganti, Francesco, Allen, Clare, Stavrinides, Vasilis, Stabile, Armando, Haider, Aiman, Freeman, Alex, Pashayan, Nora, Punwani, Shonit, Emberton, Mark, Moore, Caroline M, Kirkham, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2022
Materias:	Innovations in prostate cancer special feature: Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978245/ https://www.ncbi.nlm.nih.gov/pubmed/34233491 http://dx.doi.org/10.1259/bjr.20210321

Ejemplares similares

Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score
por: Giganti, Francesco, et al.
Publicado: (2022)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort
por: Giganti, Francesco, et al.
Publicado: (2020)

Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study [Image: see text] ()
por: Stavrinides, Vasilis, et al.
Publicado: (2020)

Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models
por: Stavrinides, Vasilis, et al.
Publicado: (2021)

Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study
por: Giganti, Francesco, et al.
Publicado: (2019)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS [Image: see text] ()
por: Stavrinides, Vasilis, et al.
Publicado: (2021)

Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis
por: Norris, Joseph M., et al.
Publicado: (2020)

Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial
por: Giganti, Francesco, et al.
Publicado: (2021)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

Partial-gland Cryoablation Outcomes for Localized Prostate Cancer in Patients with Magnetic Resonance Imaging (MRI)-visible and MRI-invisible Lesions
por: Zhu, Alec, et al.
Publicado: (2023)

Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer
por: Riskin-Jones, Hannah, et al.
Publicado: (2020)

A Systematic Review of Patient Race, Ethnicity, Socioeconomic Status, and Educational Attainment in Prostate Cancer Treatment Randomised Trials—Is the Evidence Base Applicable to the General Patient Population?
por: Patki, Siddhant, et al.
Publicado: (2023)

Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022)

Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists
por: Giganti, Francesco, et al.
Publicado: (2021)

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial
por: Pasquier, David, et al.
Publicado: (2023)

Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting
por: Donaldson, Ian A., et al.
Publicado: (2015)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
por: Barrett, Tristan, et al.
Publicado: (2022)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study
por: Brembilla, Giorgio, et al.
Publicado: (2022)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

Fear of Recurrence in Prostate Cancer Patients: A Cross-sectional Study After Radical Prostatectomy or Active Surveillance
por: Nilsson, Rasmus, et al.
Publicado: (2021)

Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023)

Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
por: Press, Benjamin H., et al.
Publicado: (2022)

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy
por: Jensen, Lindsay, et al.
Publicado: (2017)

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
por: Beckmann, Kerri, et al.
Publicado: (2021)

Prospective Long-term Health-related Quality of Life Outcomes After Surgery, Radiotherapy, or Active Surveillance for Localized Prostate Cancer
por: Kord, Eyal, et al.
Publicado: (2022)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non–protocol-based Follow-up and a Protocol-based Contemporary Follow-up
por: Kalalahti, Inari, et al.
Publicado: (2021)

Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
por: Singh, Paras B., et al.
Publicado: (2014)

Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
por: Kensler, Kevin H., et al.
Publicado: (2022)

The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review
por: Valerio, Massimo, et al.
Publicado: (2014)

Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?
por: Rakauskas, Arnas, et al.
Publicado: (2021)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017)

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital
por: Kan, Carolyn K., et al.
Publicado: (2017)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
por: Wang, Wei Gang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ccjpcogrbagbiiq4ek379shgpg